298 related articles for article (PubMed ID: 36971240)
1. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
4. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
5. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
7. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
9. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
10. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
12. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
[TBL] [Abstract][Full Text] [Related]
14. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
18. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
19. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
Fu Y; Zhang Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
[TBL] [Abstract][Full Text] [Related]
20. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
Chen J; Tang P; Wang Y; Wang J; Yang C; Li Y; Yang G; Wu F; Zhang J; Ouyang L
J Med Chem; 2022 Apr; 65(7):5184-5211. PubMed ID: 35324195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]